World-first psilocin binge eating disorder trial reveals improvement in all patients
Swinburne University of Technology and Entropy Neurodynamics' world's first IV-infused psilocin binge-eating disorder trial has led to improvements in all participants.
A world-first clinical trial of IV-infused psilocin for binge-eating disorder has shown remarkable results, with all participants experiencing improvements. After just two treatments, 50% of patients did not experience any binge-eating episodes during the 84-day follow-up period. The pilot trial achieved a 73% reduction in binge-eating episodes for the six patients who were previously treatment-resistant, and also led to significant reductions in anxiety, depression, and an overall 61% improvement in quality of life.
Swinburne University of Technology's director of clinical trials, Susan Rossell, expressed delight at maintaining the trial's success at the four-week mark, as these patients had previously struggled with the disorder for up to 20 years and had previously failed treatments. Prior to the study, these patients averaged 2.3 binge-eating episodes per week.
Entropy Neurodynamics CEO Jason Carroll emphasized the encouraging nature of the 12-week results, stating that the goal is not to develop a daily medication, but to investigate if a limited number of precision-controlled psychedelic treatments can provide lasting benefits after the treatment has ended. The researchers believe these early data from a small study provide strong clinical validation for continued development of the precision-controlled approach TRP-8803.
Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
